Modality
mRNA
MOA
Menini
Target
MDM2
Pathway
Fibrosis
IgANPompeEoE
Development Pipeline
Preclinical
~Nov 2018
→ ~Feb 2020
Phase 1
~May 2020
→ ~Aug 2021
Phase 2
Nov 2021
→ Jan 2030
Phase 2Current
NCT08889987
101 pts·EoE
2021-11→2027-10·Completed
NCT03789712
1,229 pts·IgAN
2022-11→2030-01·Recruiting
1,330 total pts2 indications
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2027-10-201.6y awayPh3 Readout· EoE
2030-01-083.8y awayPh3 Readout· IgAN
Trial Timeline
Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030
P2/3
Complet…
P2/3
Recruit…
Catalysts
Ph3 Readout
2027-10-20 · 1.6y away
EoE
Ph3 Readout
2030-01-08 · 3.8y away
IgAN
RecruitingCompleted|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08889987 | Phase 2/3 | EoE | Completed | 101 | 6MWD |
| NCT03789712 | Phase 2/3 | IgAN | Recruiting | 1229 | CR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Mavutenlimab | Johnson & Johnson | Phase 3 | Cl18.2 | |
| LLY-6079 | Eli Lilly | Phase 2 | MDM2 | |
| Ivorelsin | Eli Lilly | Approved | JAK1 | |
| LLY-3251 | Eli Lilly | Phase 2 | MDM2 | |
| NVO-2974 | Novo Nordisk | NDA/BLA | PARP | |
| GSK-7987 | GSK | Phase 3 | MDM2 | |
| AMG-2752 | Amgen | Preclinical | MDM2 | |
| REG-3155 | Regeneron | Phase 1/2 | MDM2 | |
| SRP-1135 | Sarepta | Phase 2/3 | MDM2 | |
| Olpafutibatinib | Immunocore | Approved | SMN2 |